SCOTT D SANDELL
CIK 1237289 · last filed 2026-07-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$23.51B
Companies
79
Total Filings
314
Lifetime Open-Market Net
-$149.76M
Filer Profile
Reported Address
1954 GREENSPRING DRIVESUITE 600
TIMONIUM, MD 21093
Related Filers
FOREST BASKETT — 102 joint filings, latest 2025-03-14
PETER J BARRIS — 84 joint filings, latest 2019-11-29
M JAMES BARRETT — 71 joint filings, latest 2018-10-24
PATRICK J KERINS — 70 joint filings, latest 2024-05-15
NEA PARTNERS 10 L P — 47 joint filings, latest 2021-07-07
NEA 12 GP, LLC — 43 joint filings, latest 2019-11-29
NEA Partners 12, Limited Partnership — 43 joint filings, latest 2019-11-29
ENTERPRISE ASSOCIATES 10 L P NEW — 42 joint filings, latest 2020-04-29
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NET | Director | 185,912 | $306.53 | $56.99M | -$139.03M | 26 | 2026-07-02 |
| COUR | Director | 2,312,113 | $5.22 | $12.07M | $0 | 12 | 2026-06-15 |
| KRRO | 10%+ Owner | 1,297,893 | $13.81 | $17.92M | $3.30M | 2 | 2026-03-12 |
| SGP | 10%+ Owner | 5,097,538 | $27.52 | $140.28M | $15.00M | 1 | 2026-02-11 |
| NeueHealth, Inc. (BHG) Delisted | Director | 674,830 | $16.35 | $11.03M | $34.97M | 8 | 2025-10-06 |
| SNTI | 10%+ Owner | 3,775,615 | $0.31 | $1.16M | $0 | 1 | 2025-03-12 |
| NeueHealth, Inc. (NEUE) Delisted | 10%+ Owner | — | $6.75 | — | $0 | 2 | 2024-10-03 |
| MBX | 10%+ Owner | 1,023,103 | $59.02 | $60.38M | $8.00M | 1 | 2024-09-17 |
| SGMT | 10%+ Owner | 3,000,275 | $10.88 | $32.64M | $0 | 1 | 2024-01-31 |
| SVRA | 10%+ Owner | 24,471,264 | $5.30 | $129.70M | $1000.0K | 1 | 2023-07-19 |
| MIRM | 10%+ Owner | 163 | $98.22 | $16.0K | $6.75M | 2 | 2023-06-15 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | 10%+ Owner | 22,372 | $15.70 | $351.2K | -$5.04M | 6 | 2023-01-27 |
| Arcellx, Inc. (ACLX) Delisted | 10%+ Owner | 6,746,494 | $115.07 | $776.32M | $39.98M | 3 | 2022-12-27 |
| Akouos, Inc. (AKUS) Delisted | 10%+ Owner | 0 | $13.29 | $0 | $10.00M | 2 | 2022-12-02 |
| IONQ.WS | 10%+ Owner | 1,141 | $25.41 | $29.0K | $0 | 1 | 2022-11-18 |
| AVEO PHARMACEUTICALS, INC. (AVEO) Delisted | 10%+ Owner | 386 | $15.00 | $5.8K | $24.62M | 17 | 2022-10-21 |
| GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | 10%+ Owner | 0 | $0.00 | $0 | $21.03M | 4 | 2022-05-26 |
| HOOD | Director | 0 | $112.57 | $0 | -$123.2K | 9 | 2022-05-16 |
| TRVI | 10%+ Owner | 10,421,428 | $15.90 | $165.70M | $31.80M | 4 | 2022-04-13 |
| Enliven Therapeutics, Inc. (IMRA) Delisted | 10%+ Owner | 716,628 | $14.59 | $10.46M | -$6.01M | 1 | 2022-04-07 |
| BE | Director | 55,751 | $275.75 | $15.37M | $20.00M | 14 | 2022-04-01 |
| Casper Sleep Inc. (CSPR) Delisted | 10%+ Owner | 0 | $6.78 | $0 | $0 | 1 | 2022-01-26 |
| ARDX | 10%+ Owner | 47 | $3.58 | $168 | $80.74M | 13 | 2021-12-27 |
| Metacrine, Inc. (MTCR) Delisted | 10%+ Owner | 2,563,257 | $0.49 | $1.27M | $9.51M | 2 | 2021-12-27 |
| CVRX | 10%+ Owner | 1,800,583 | $2.88 | $5.19M | $9.01M | 1 | 2021-07-07 |
| GLUE | 10%+ Owner | 7,692,298 | $14.07 | $108.23M | $19.95M | 1 | 2021-06-30 |
| Desktop Metal, Inc. (DM) Delisted | 10%+ Owner | 554 | $4.96 | $2.7K | $0 | 1 | 2021-06-10 |
| Eargo, Inc. (EAR) Delisted | 10%+ Owner | 10 | $2.57 | $26 | $5.60M | 2 | 2021-05-26 |
| MRKR | 10%+ Owner | 1,071,428 | $1.15 | $1.23M | $10.00M | 1 | 2021-03-18 |
| Regulus Therapeutics Inc. (RGLS) Delisted | 10%+ Owner | 645,106 | $8.16 | $5.26M | $3.96M | 3 | 2020-12-07 |
| SPT | 10%+ Owner | 165,945 | $10.80 | $1.79M | $0 | 1 | 2020-11-17 |
| Mersana Therapeutics, Inc. (MRSN) Delisted | 10%+ Owner | 478,791 | $29.08 | $13.92M | $14.77M | 5 | 2020-09-16 |
| Inozyme Pharma, Inc. (INZY) Delisted | 10%+ Owner | 2,187,689 | $4.00 | $8.75M | $4.00M | 1 | 2020-07-28 |
| NKTX | 10%+ Owner | 2,235,449 | $2.91 | $6.51M | $12.00M | 1 | 2020-07-16 |
| SENS | 10%+ Owner | 993,368 | $8.71 | $8.65M | $27.21M | 5 | 2020-04-23 |
| Adaptimmune Therapeutics PLC (ADAP) Delisted | 10%+ Owner | 19,500,000 | $0.06 | $1.13M | $5.00M | 1 | 2020-01-28 |
| TESARO, Inc. (TSRO) Delisted | 10%+ Owner | 0 | — | — | $73.03M | 7 | 2019-01-22 |
| ESTC | 10%+ Owner | 655,522 | $83.39 | $54.66M | $0 | 1 | 2018-10-10 |
| ASND | 10%+ Owner | 82,978,668 | $263.51 | $21.87B | $49.02M | 4 | 2018-09-10 |
| Surface Oncology, Inc. (SURF) Delisted | 10%+ Owner | 3,179,544 | $1.07 | $3.40M | $2.00M | 1 | 2018-04-23 |
| Oruka Therapeutics, Inc. (ABIO) Delisted | 10%+ Owner | 0 | $28.80 | $0 | -$731.3K | 1 | 2018-02-27 |
| Cascadian Therapeutics, Inc. (CASC) Delisted | 10%+ Owner | 10,882,574 | — | — | $0 | 1 | 2018-02-22 |
| APPN | 10%+ Owner | 9,628 | $34.76 | $334.7K | -$66.07M | 4 | 2018-02-15 |
| SYNLOGIC, INC. (SYBX) Delisted | 10%+ Owner | 281,929 | $0.69 | $194.5K | $0 | 2 | 2018-01-26 |
| Care.com Inc (CRCM) Delisted | 10%+ Owner | 504 | — | — | $0 | 2 | 2017-11-08 |
| RYTM | 10%+ Owner | 4,359,956 | $104.71 | $456.53M | $9.35M | 1 | 2017-10-10 |
| MULESOFT, INC (MULE) Delisted | 10%+ Owner | 0 | — | — | $0 | 1 | 2017-03-22 |
| Zosano Pharma Corp (ZSAN) Delisted | 10%+ Owner | 1,361 | $0.56 | $759 | -$13.80M | 4 | 2017-02-14 |
| Achaogen, Inc. (AKAO) Delisted | 10%+ Owner | 5,215,128 | — | — | $6.75M | 1 | 2016-12-19 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | 10%+ Owner | 1,858,450 | — | — | $4.39M | 1 | 2016-10-31 |
| Roka BioScience, Inc. (ROKA) Delisted | 10%+ Owner | 321,681 | — | — | $4.60M | 3 | 2016-09-30 |
| TriVascular Technologies, Inc. (TRIV) Delisted | 10%+ Owner | 0 | — | — | $0 | 1 | 2016-02-04 |
| Epizyme, Inc. (EPZM) Delisted | 10%+ Owner | 5,854,351 | $1.47 | $8.61M | $23.87M | 4 | 2016-01-12 |
| SUPN | 10%+ Owner | 6,241,250 | $41.64 | $259.89M | $216.13M | 4 | 2015-11-12 |
| Avalo Therapeutics, Inc. (CERC.U) Delisted | 10%+ Owner | 594,245 | — | — | $0 | 1 | 2015-10-20 |
| SYNLOGIC, INC. (MIRN) Delisted | 10%+ Owner | 1,241,650 | — | — | $6.00M | 1 | 2015-10-06 |
| Vitae Pharmaceuticals, Inc (VTAE) Delisted | 10%+ Owner | 8,250 | — | — | $0 | 1 | 2015-07-02 |
| BOX | 10%+ Owner | 0 | $33.75 | $0 | $0 | 1 | 2015-01-29 |
| Tableau Software Inc (DATA) Delisted | Director | 55,705 | — | — | -$600.28M | 14 | 2014-12-08 |
| CVENT INC (CVT) Delisted | 10%+ Owner | 1,009 | $8.52 | $8.6K | -$46.31M | 5 | 2014-11-28 |
| DERM | 10%+ Owner | 3,433,810 | $7.23 | $24.83M | $1.11M | 1 | 2014-10-08 |
| Viracta Therapeutics, Inc. (SNSS) Delisted | 10%+ Owner | 1,376,495 | $18.62 | $25.63M | -$6.84M | 2 | 2014-08-29 |
| Loxo Oncology, Inc. (LOXO) Delisted | 10%+ Owner | 1,789,420 | — | — | $3.00M | 1 | 2014-08-06 |
| WDAY | Director | 9,490 | $185.70 | $1.76M | -$1.53M | 6 | 2014-03-04 |
| BOINGO WIRELESS, INC. (WIFI) Delisted | 10%+ Owner | 4,467,960 | $13.99 | $62.51M | -$27.4K | 2 | 2013-12-12 |
| FUSION-IO, INC. (FIO) Delisted | Director | 7,053,379 | — | — | -$44.65M | 19 | 2013-11-21 |
| AUDIENCE INC (ADNC) Delisted | 10%+ Owner | 1,016 | — | — | -$75.0K | 3 | 2013-11-06 |
| XOOM Corp (XOOM) Delisted | 10%+ Owner | 2,239,385 | — | — | $0 | 1 | 2013-10-31 |
| GRPN | 10%+ Owner | 0 | $18.73 | $0 | -$345.4K | 2 | 2013-09-17 |
| Clovis Oncology, Inc. (CLVS) Delisted | 10%+ Owner | 575 | $0.08 | $47 | $17.11M | 2 | 2013-06-05 |
| CHANNELADVISOR CORP (ECOM) Delisted | 10%+ Owner | 2,765,599 | $23.09 | $63.86M | $0 | 1 | 2013-05-29 |
| Millennial Media Inc. (MM) Delisted | 10%+ Owner | 8,196,614 | — | — | -$21.48M | 2 | 2012-10-30 |
| HYPERION THERAPEUTICS INC (HPTX) Delisted | 10%+ Owner | 1,513,927 | — | — | $5.00M | 1 | 2012-08-02 |
| INNERWORKINGS INC (INWK) Delisted | 10%+ Owner | 4,529,190 | — | — | -$12.65M | 7 | 2012-03-30 |
| ECHO | 10%+ Owner | 901 | $93.14 | $83.9K | $0 | 1 | 2012-03-01 |
| VG | 10%+ Owner | 4,558,701 | $15.80 | $72.03M | $0 | 1 | 2011-03-15 |
| INHIBITEX, INC. (INHX) Delisted | 10%+ Owner | 6,898,294 | — | — | $3.00M | 1 | 2009-10-30 |
| Data Domain, Inc. (DDUP) Delisted | Director | 43,750 | — | — | -$27.33M | 12 | 2009-07-21 |
| TNDM | 10%+ Owner | 592,747 | $17.11 | $10.14M | $0 | 1 | 2007-11-09 |
Recent Filings · Page 11 of 32
314 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-07-28 | GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Buy (P) | +3,151,260 | $7.09M | EDGAR |
| 2020-07-16 | NKTX | Mixed | +2,902,115 | $12.00M | EDGAR |
| 2020-07-07 | ARDX | Gift (G) | −14,258 | $0 | EDGAR |
| 2020-07-01 | Akouos, Inc. (AKUS) Delisted | Mixed | +4,294,207 | $10.00M | EDGAR |
| 2020-06-22 | AVEO PHARMACEUTICALS, INC. (AVEO) Delisted | Buy (P) | +1,428,571 | $7.50M | EDGAR |
| 2020-06-17 | ARDX | Sell (S) | −43 | -$274 | EDGAR |
| 2020-06-12 | ARDX | Mixed | −2,485,605 | -$573.1K | EDGAR |
| 2020-06-03 | NET | Grant (A) | +6,622 | $0 | EDGAR |
| 2020-05-21 | NET | Mixed | +43,333 | -$9.64M | EDGAR |
| 2020-05-14 | BE | Grant (A) | +19,813 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.